BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2013

View Archived Issues

M01ZH09 provides little protection against typhoid challenge

Read More

First report of HIV proviral DNA level modulation in response to AGS-004 immunotherapy

Read More

FOB Synthesis identifies novel anti-Acinetobacter carbapenem antibiotic

Read More

BiondVax receives European FP7 grant to develop lead influenza vaccine

Read More

Human Brain Project launched with inaugural summit in Lausanne

Read More

Preclinical pharmacokinetics characterized for novel candidate for metabolic disorders

Read More

OncoTherapy Science presents phase II results for OTS-102 in biliary tract cancer

Read More

Lundbeck and Otsuka begin phase III program for add-on therapy in Alzheimer's disease

Read More

Joslin Diabetes Center and Johnson & Johnson partner to identify therapeutic targets in diabetes

Read More

Novel compounds inhibit drug-resistant mutants of the influenza A virus M2 proton channel

Read More

Biota Pharmaceuticals discloses new DNA gyrase inhibitors for bacterial infection treatment

Read More

Linx Pharmaceutical reports discovery of apoptosis inhibitors

Read More

New kinesin-like protein KIF11 inhibitors discovered by Pharma Valley and Taiho

Read More

Seragon Pharmaceuticals patents new ER-alpha ligands

Read More

Genosco and Oscotec disclose new FLT3 kinase inhibitors

Read More

Dynavax begins first human trial of AZD-1419

Read More

Pergamum reports final data from phase I/II LL-37 study in chronic leg ulcers

Read More

Alkermes' ALKS-5461 receives fast track designation for major depressive disorder

Read More

Heptares/MorphoSys GPCR collaboration reaches first milestone

Read More

Relypsa announces topline data from second part of patiromer phase III trial

Read More

Cystic Fibrosis Foundation awards grant for BET bromodomain inhibitor research

Read More

Medivir selects a candidate drug for neuropathic pain

Read More

Rexahn Pharmaceuticals in-licenses oligonucleotide targeted drug delivery platform

Read More

Recruitment in phase III trial of novel mono-pegylated interferon alpha 2b under way

Read More

Japanese encephalitis vaccine prequalified by WHO for use in children

Read More

Evotec and Harvard form new research collaboration

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 18, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 18, 2025.
  • GLP-1 capsule

    Maintenance, man: Lilly’s phase III weight trial hits goals

    BioWorld
    Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
  • Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

    AI drug developer Insilico to raise $292 million in Hong Kong IPO

    BioWorld
    Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing